A

Aerium Therapeutics

20 employees

Aerium Therapeutics is discovering and developing novel monoclonal antibodies (mAbs) and antiviral treatments against SARS-CoV-2 variants.

Basic info

Industry

pharmaceutical manufacturing

Sectors

Health Care
Therapeutics
Medical
Pharmaceutical
Biopharma

Date founded

2021

Funding rounds raised

A

Aerium Therapeutics raised undisclosed on March 22, 2022

Investors: Omega Funds and F-Prime Capital Partners

FAQ